NYSE · Healthcare · Diagnostics & Research · USA
Thermo Fisher Scientific Inc is a mega cap company (market value over $200 billion) in the Diagnostics & Research industry.
Thermo Fisher Scientific provides scientific equipment, reagents and services to customers in pharmaceutical, biotech, healthcare, academic and government sectors. The company delivers products for life sciences research, analytical testing, diagnostic applications and laboratory supplies, alongside pharmaceutical development and manufacturing services. Its brands include Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Thermo Fisher Scientific Inc stock.
Overvalued: intrinsic value $266.81 per share, market price $679.38, margin of safety -154.6% (as of 2026-10-19).
Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $266.81; the price of $679.38 is 155% above that value, and 76% of that value comes from beyond year five.
Leak Score: 46/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
10 more in this industry show a wider margin of safety.
TMO is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $266.81; the price of $679.38 is 155% above that value, and 76% of that value comes from beyond year five.
$266.81 per share (as of the 2026-10-19 close), against a market price of $679.38. That is a margin of safety of -154.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price needs faster growth than we project for any company. It is betting on an exception. Yearly sales growth the price needs: 37.5%. Yearly sales growth it has sustained: 3.9%.
46 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.